Back to top

Image: Bigstock

Aerie Pharmaceuticals, Inc.

Read MoreHide Full Article

Aerie’s reported a wider-than-expected loss in the second quarter. Moreover, estimates have declined significantly post  second-quarter results. Nevertheless, we are positive on the Aerie’s efforts in developing its pipeline candidates. Aerie plans to file a new drug application for its lead candidate, Rhopressa, in the U.S. in the third quarter of 2016. A potential approval and successful commercialization of the drug will significantly boost the company’s growth prospects as glaucoma is one of the largest segments in the global ophthalmic market. We are also positive with Aerie’s second late-stage glaucoma candidate, Roclatan, which is being evaluated for lowering intraocular pressure in patients suffering from open-angle glaucoma and ocular hypertension. With no approved product in its portfolio, any regulatory setback would have an adverse impact on the stock. Stiff competition in the glaucoma market is also concerning.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Aerie Pharmaceuticals, Inc. (AERI) - free report >>

Published in